Successful Treatment of a Patient With Severe COVID-19 Using an Integrated Approach Addressing Mast Cells and Their Mediators.

• COVID-19 has no distinct pathogenesis or effective treatment. • COVID-19 could progress to a stage requiring lung transplant. • Symptoms of patients with COVID-19 may involve mast cell activation. • COVID-19 involves proinflammatory mediators released from mast cells. • A patient with severe COVID-19 improved by addressing mast cell activation. SARS-CoV-2 infects cells, leading to a complex immune response that involves the release of mediators, most of which are released from mast cells, leading to lung edema, fibrosis, inflammation, and microthromboses—hallmarks of COVID-19. Here, we report on a patient who was initially hospitalized with severe COVID-19 pneumonia as well as physical and mental fatigue. Despite having been treated with albuterol, azithromycin, ceftriaxone, convalescent plasma, and dexamethasone, her condition continued to worsen to the extent that she was considered for double lung transplant. Four months after a novel integrative treatment approach that primarily aimed at inhibiting mast cells and their mediators, using rupatadine, famotidine, misoprostol, vitamin D3 luteolin, quercetin, and erythropoietin, the patient recovered fully. [ABSTRACT FROM AUTHOR]